Bavarian Nordic Announces Interim Results for the First Three Months of 2019

    NEXT STORY
    Centauri’s AlphamerTM Platform highlighted at 4th Annual Advances in Immuno-Oncology Congress
    PREV STORY
    Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Novo Nordisk submits application to regulatory authorities to include LEADER data in Victoza® label

    Bagsværd, Denmark, 25 October 2016 - Novo Nordisk today announced the submission of a ...

    author_avatar
    NASDAQ Market News

    OSE Immunotherapeutics Announces Licensing Deal for Neoepitope Combination Tedopi® in Korea with Chong Kun Dang Pharmaceutical Corporation

    author_avatar
    NASDAQ Market News

    Selecta Biosciences to Report Third Quarter 2017 Financial Results and Updated Phase 2 Data for SEL-212 on Tuesday, November 7, 2017

    WATERTOWN, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage ...

    author_avatar
    NASDAQ Market News